Group 1 - Mirxes-B (2629.HK) experienced a significant price surge, rising over 35% to reach 75 HKD, marking a new all-time high since its IPO [1] - The company's market capitalization has surpassed 20 billion HKD [1] - Since its listing on May 23, the stock price has increased by 220% from the IPO price of 23.3 HKD [1] Group 2 - Mirxes is a Singapore-based company specializing in microRNA technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company was recently included in the Hang Seng Composite Index, effective from September 8, and has officially become a Hong Kong Stock Connect eligible stock [1]

智通财经5月22日电，利弗莫尔证券显示，新加坡微小核糖核酸(miRNA)技术公司Mirxes-B明日挂牌， 今日暗盘交易时段一度涨超40%。 ...